Goldman Sees Obesity-Drug Market Growing to $130 Billion by 2030
- Firm’s previous estimate was for sales to reach $100 billion
- Approval of Lilly’s Zepbound is among reasons for the boost
This article is for subscribers only.
Goldman Sachs Group Inc. sees growing potential for the global market for weight-loss drugs by the end of the decade.
The obesity market — currently dominated by Novo Nordisk A/S and Eli Lilly & Co. — is now set to reach $130 billion by 2030, according to Goldman Sachs analysts led by Chris Shibutani. That’s up from a prior forecast of $100 billion.